Binex Co

Binex Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Binex Co (053030.KQ) as of Nov 2, 2026 is -1.93 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -36.89 B KRW — a change of -94.77% (higher).

EBITDA

-1.93 BKRW

YoY

-94.77%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Binex Co is 2025 -1.93 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Binex Co was 2024 -36.89 B KRW. It decreases by -94.77% higher compared to the previous year.

The Binex Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
7.56 B KRW
Jan 1, 2019
12.02 B KRW
Jan 1, 2020
7.99 B KRW
Jan 1, 2021
13.20 B KRW
Jan 1, 2022
17.47 B KRW
Jan 1, 2023
3.66 B KRW
Jan 1, 2024
-36.89 B KRW
Jan 1, 2025
-1.93 B KRW
The Binex Co EBITDA history
YEAREBITDAYoY
-1.93 BKRW-94.77%
-36.89 BKRW-1,108.46%
3.66 BKRW-79.06%
17.47 BKRW+32.33%
13.20 BKRW+65.23%
7.99 BKRW-33.53%
12.02 BKRW+59.05%
7.56 BKRW-194.89%
-7.96 BKRW+300.57%
-1.99 BKRW+306.43%
-489.12 MKRW-117.61%
2.78 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Binex Co Stock analysis

What does Binex Co do? Binex Co Ltd generates revenue through the manufacturing and sale of pharmaceutical products including digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal tract regulators, antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, and various ointments and creams. The company also produces bio medicines and raw materials. Binex Co Ltd distributes its products domestically within Busan and to overseas markets, targeting healthcare providers, pharmacies, and hospitals that purchase pharmaceuticals for patient care and treatment. The firm's product portfolio covers a wide range of therapeutic areas, including gastrointestinal health, cardiovascular support, pain management, respiratory care, and chronic disease management. By offering both branded and generic pharmaceutical solutions, Binex Co Ltd serves diverse customer segments across the domestic and international pharmaceutical markets, leveraging its manufacturing capabilities to meet regional healthcare demands. Binex Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Binex Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Binex Co is -1.93 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Binex Co changed from -36.89 B KRW to -1.93 B KRW, representing a -94.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Binex Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Binex Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Binex Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Binex Co